The Oncology Institute Stock Price, News & Analysis

The Oncology Institute, Inc. (NASDAQ: TOI) is a healthcare company focused on oncology care in the community setting. According to the company, it is one of the largest value-based oncology groups in the United States and operates within the health care and social assistance sector. TOI states that it is advancing oncology by delivering highly specialized, value-based cancer care outside of traditional hospital environments, with an emphasis on evidence-based medicine and cost-effective care for cancer patients.

Founded in 2007, The Oncology Institute describes itself as a pioneer in value-based community oncology care. The company reports that it offers cancer care to a population of approximately 1.9 million patients through over 180 employed and affiliate clinicians and more than 100 clinics and affiliate locations of care across five states. TOI highlights that it is changing oncology for the better by pairing specialized clinical expertise with care models that are designed to manage total cost of care while maintaining quality.

Business model and care approach

The Oncology Institute presents its business as centered on value-based cancer care delivered in the community setting. In its public statements, TOI characterizes itself as a value-based oncology group and a value-based oncology practice. This reflects a focus on arrangements where reimbursement is tied to quality and cost outcomes rather than only to the volume of services. The company also references delegated capitated models and capitation revenue in its outlook, indicating that some of its contracts involve fixed payments per patient for comprehensive oncology services.

TOI notes that it participates in models sponsored by the Centers for Medicare & Medicaid Services (CMS), including the Enhancing Oncology Model. Through its California professional corporation, the company reports having generated Medicare savings in this program while earning high quality scores on measures such as avoidable emergency department visits and admissions. TOI links these results to programs such as its High Value Cancer Care program, health care coaching, and 24/7 symptom management support designed to keep patients on treatment and reduce unnecessary hospital utilization.

Clinical services and care delivery

According to TOI’s own descriptions, the organization offers evidence-based cancer care that includes access to clinical trials and transfusions. The company states that it delivers care models traditionally associated with advanced care delivery organizations, but in community locations. In earlier descriptions, TOI has also referenced services such as infusion centers, an in-house dispensary, outpatient blood transfusion, outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. These services are grouped into operating segments that include a dispensary segment, patient services, and clinical trials and others, with patient services identified as the primary source of revenue.

TOI emphasizes that its model is designed to bring specialized oncology care closer to where patients live. It describes its clinics and affiliate locations as community-based, and it highlights the combination of clinical trials and other advanced care delivery models with local access. The company also notes that patients across its markets have access to best practices developed in its value-based programs, such as proactive navigation and real-time symptom management.

Scale, footprint, and organization

The Oncology Institute reports that it serves a large and growing patient base through a network of clinics and affiliated sites. Public communications from the company state that TOI has over 180 employed and affiliate clinicians and more than 100 clinics and affiliate locations of care across five states. TOI also notes that it is expanding delegated contracts in markets such as Florida and that it operates a pharmacy and dispensary business that contributes meaningfully to revenue and gross profit.

The company is headquartered in Cerritos, California, as reflected in its SEC filings, and its common stock and redeemable warrants trade on The Nasdaq Stock Market LLC under the symbols TOI and TOIIW, respectively. TOI identifies itself as an emerging growth company in certain SEC filings, which can affect its reporting and disclosure framework under U.S. securities laws.

Technology, operations, and partnerships

In its public updates, TOI has highlighted the use of technology and automation to support its operations. The company has described efforts to leverage artificial intelligence to drive efficiencies in operations and improve the patient experience. For example, TOI announced a co-development partnership with Ascertain, a healthcare technology company, to create near-touchless administrative workflows for payer-related tasks ahead of outpatient oncology visits. The collaboration uses an AI-powered automation module to streamline prior authorization processes and other payer interactions, with TOI reporting substantial reductions in authorization workload and submission time at pilot sites.

TOI has also referenced a technology-enabled care delivery platform and enterprise-level data privacy and security practices in connection with its leadership appointments. These statements indicate that the company views technology and data as important components of its value-based care model and operational strategy.

Participation in value-based programs and Medicare models

The Oncology Institute has publicly discussed its participation in CMS programs aimed at advancing high-quality, person-centered, and equitable cancer care. In particular, the company has reported results from the Enhancing Oncology Model, a voluntary total-cost-of-care model for Medicare Fee-for-Service beneficiaries. TOI states that it achieved Medicare savings and earned maximum quality points on certain measures, attributing these outcomes to proactive navigation, high-value care programs, and around-the-clock symptom management support.

The company also notes a prior track record in CMS’s Oncology Care Model, where it reports having exceeded quality standards and generated savings for Medicare. These disclosures underscore TOI’s emphasis on value-based arrangements and its focus on both clinical outcomes and cost management within oncology.

Financial orientation and segments

In its communications to investors, The Oncology Institute has described its revenue mix and operating segments. The company identifies three operating segments: dispensary, patient services, and clinical trials and others. It has stated that key revenue is earned from providing patient services and that the majority of revenue comes from patient services. TOI has also discussed fee-for-service revenue growth, retail pharmacy and dispensary performance, and capitation revenue as components of its financial profile.

TOI uses non-GAAP metrics such as Adjusted EBITDA and Free Cash Flow as additional tools to assess operational and financial performance, as described in its press releases and SEC filings. The company provides reconciliations of these measures to the most comparable GAAP metrics and explains the types of adjustments included, such as depreciation, amortization, interest, taxes, non-cash items, share-based compensation, changes in fair value of liabilities, and certain consulting and infrastructure costs.

Stock listing and regulatory disclosures

The Oncology Institute, Inc. files periodic and current reports with the U.S. Securities and Exchange Commission. Its common stock, with a par value of $0.0001 per share, is listed on Nasdaq under the symbol TOI, and its redeemable warrants are listed under the symbol TOIIW. SEC filings indicate that the company has reported various material events, including financial results, guidance updates, cybersecurity incidents affecting a software provider, changes to the Board of Directors, and the use of investor presentations.

Through these filings, TOI provides information on its financial condition, results of operations, governance changes, and certain operational developments. Investors can review these documents for detailed historical financial data, risk factors, and descriptions of non-GAAP measures used by the company.

FAQs about The Oncology Institute, Inc.

• What does The Oncology Institute, Inc. do?
  The Oncology Institute, Inc. focuses on delivering specialized oncology care in the community setting. The company describes itself as a value-based oncology group that provides evidence-based cancer care, including access to clinical trials and transfusions, through clinics and affiliate locations across multiple states.
• How does The Oncology Institute describe its business model?
  TOI characterizes its business model as value-based cancer care. It references delegated capitated arrangements and capitation revenue, participation in CMS total-cost-of-care models, and programs designed to reduce avoidable emergency department visits and admissions while maintaining or improving quality of care.
• Where does The Oncology Institute operate?
  The company reports that it has over 100 clinics and affiliate locations of care across five states. It also notes activity in specific markets such as Florida and Oregon in connection with growth in fee-for-service revenue and delegated contracts.
• What types of services does TOI mention providing?
  In its descriptions, TOI mentions services such as infusion centers, an in-house dispensary, outpatient blood transfusion, outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. These services are organized into segments including dispensary, patient services, and clinical trials and others.
• How does The Oncology Institute participate in Medicare models?
  TOI reports participation in CMS programs such as the Enhancing Oncology Model and previously the Oncology Care Model. It has disclosed that it achieved Medicare savings and high quality scores in these programs through initiatives like its High Value Cancer Care program and 24/7 symptom management support.
• What role does technology play at TOI?
  The company has highlighted a technology-enabled care delivery platform and efforts to leverage AI to improve operational efficiency and the patient experience. TOI has also announced a partnership with Ascertain to co-develop AI-based automation for administrative workflows such as prior authorizations.
• How is The Oncology Institute structured from a revenue perspective?
  TOI describes three operating segments: dispensary, patient services, and clinical trials and others. It states that key revenue is earned from providing patient services and that the majority of revenue is from patient services, with additional contributions from dispensary and other segments.
• On which exchange is TOI stock listed?
  According to its SEC filings, The Oncology Institute, Inc.’s common stock is listed on The Nasdaq Stock Market LLC under the ticker symbol TOI. Its redeemable warrants are listed on Nasdaq under the symbol TOIIW.
• When was The Oncology Institute founded?
  Public company materials state that The Oncology Institute was founded in 2007. Since then, it has developed a network of clinicians and clinics focused on value-based community oncology care.
• Is The Oncology Institute involved in clinical trials?
  Yes. TOI notes that it offers clinical trials as part of its evidence-based cancer care and that clinical trials are included within its operating segments. The company highlights clinical trials as one of the care delivery models it brings into community settings.